At the end of 2019, 25.4 million of the 38.0 million people living with HIV were receiving antiretroviral therapy — a number that has more than tripled since 2010. Moreover, we have begun to see a shift from antiretroviral therapies to novel treatments such as single dose medications and injections.

This progress represents a step towards reaching the UNAIDS 90:90:90 agenda. Despite this, the road ahead for treating and preventing HIV comes with a number of challenges when it comes to pharma R&D. These challenges stem, in large part, from the fact that HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies.

In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment that have potential to reduce new HIV infections to a level where it is no longer considered a public health threat. Read the whitepaper to explore:

• The state of the current HIV treatment landscape, specifically treatments like pre-exposure prophylaxis (PrEP)
• Patients’ barriers to usage and the need for improved adherence to oral HIV therapies
• Innovations on the horizon for HIV treatment and prevention, including broadly neutralising antibodies (bNAbs), gene-based therapies and CAR T-cell immunotherapies
• Benefits of incorporating elements of decentralised and agile clinical trials for HIV R&D
• Considerations for patient-centricity when designing trials for people at-risk or living with HIV
• Digital health technologies used to measure adherence to antiretroviral therapies
• The new outlook for HIV for 2021 and beyond